| Abstract [eng] |
The aim of the study was to evaluate the value of platelets as inflammatory cells in early stages of cardiovascular diseases (CVD) and metabolic syndrome (MS) in the context of traditional and by applying the new biomarkers of atherosclerosis. For the first time in Lithuania, we have found that cyclophilin A (CyPA) test is not suitable for early detection and prognosis of CVD and MS. It is evident that the determined link between CyPA and platelets-monocytes complexes shows protein’s liaison with inflammatory processes, but not the platelet function. We have determined that platelet function in men with dyslipidaemia and other traditional risk factors of CVD and MS is prone to increased reactivity, which can be considered as independent risk factor of CVD, but not the MS. Identified links between platelet functions and inflammatory processes were week and indirect. Presumably, platelets are involved in the platelet driven thrombosis, but not inflammatory processes, which determine development of CVD and MS. We have also defined that ratios of lipid metabolism markers are independent prognostic markers of CVD and MS, and allow individuals to be differentiated between CVD cases and those who are only affected by the risk factors. For the first time we have established lipid-CRP ratios, which can be used as additional valuable tool for the estimation of risk of CVD, but not MS. We found that CRP position in numerator of lipid-CRP ratios demonstrates better value for prediction of CVD. Furthermore, we have determined that increased values of inflammatory markers (CRP, fibrinogen and vWF) in men with dyslipidaemia and other traditional risk factors of CVD and MS are independent risk factors of CVD, but not MS. |
